• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

Drug for children with spinal muscular atrophy too expensive, HSE says

firstwordpharmaFebruary 23, 2019

Tag: HSE , Spinal Muscular Atrophy , Children

  • The Health Service Executive has determined that the spinal muscle atrophy drug Spinraza is not cost-effective at its current price, The Irish Times reported Friday.

  • The HSE determined that the treatment could carry a cost of 20 million euros over five years, while it was not able to reach an accord with the manufacturer regarding a viable price.

  • The regulator noted that Spinraza would carry a cost of  600 000 euros for the first year and 380 000 euros for each successive year.

  • The HSE stated that it was "obligated to ensure that expenditure of this scale must represent evidence of clinical and cost-effectiveness."

  • Register as Visitor to CPhI China 2019!

Previous:Delhi HC sets aside govt ban on Lupin's anti-diabetic drug Gluconorm-30

Next:Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Drug for children with spinal muscular atrophy too expensive, HSE says | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

You may like
More>>

FMOC-L-HSE(TRT)-OH

FMOC-L-HSE(TRT)-OH
Children

Children
Identification Band (Adult, Children)

Identification Band (Adult, Children)
printed children resistant foil

printed children resistant foil

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service